Table 1.
Clinical and laboratory characteristics for the entire patient cohort, patients without and with primary outcome event (prim outcome), healthy controls and all Swedish stroke patients (data from the Swedish Stroke Register)
| Patient cohort | Patient without prim outcome | Patient with prim outcome | Healthy controls | Stroke register 2011 | |
|---|---|---|---|---|---|
| N = 211 | N = 157 | N = 54 | N = 53 | N ≈ 25,000 | |
| Age at inclusion (years) | 72.3 ± 8.2 | 71.5 ± 8.2 | 74.4 ± 7.9* | 70.4 ± 7.8 | 75.9 |
| Female (n (%)) | 89 (42%) | 72 (46%) | 17 (31%) | (42%) | 48% |
| Medical history at inclusion | |||||
| Hypertension (n (%)) | 139 (66%) | 101 (64%) | 39 (72%) | 61% | |
| Diabetes (n (%)) | 32 (15%) | 19 (12%) | 13 (24%)* | 24% | |
| Active smoker (n (%)) | 38 (18%) | 29 (19%) | 8 (14%) | 13% | |
| Previous IS/TIA (n (%)) | 53 (25%) | 35 (22%) | 18 (33%) | 37% | |
| IHD (n (%)) | 38 (18%) | 26 (17%) | 13 (24%) | ||
| TIA as index event (n (%)) | 72 (34%) | 54 (34%) | 17 (31%) | ||
| NIHSS | 0 (0–1) | 0 | 0 | ||
| BMI at inclusion (kg m−2) | 25.8 ± 3.8 | 25.9 ± 3.8 | 25.5 ± 3.9 | ||
| Hemoglobin (g l−1) | 141 ± 13 | 141 ± 13 | 141 ± 15 | 137 ± 10 | |
| Leukocyte count (× 109 l−1) | 6.9 (5.9–8.9) | 6.9 | 6.9 | 5.0 (4.3–5.5) | |
| Platelet count (× 109 l−1) | 214 (181–262) | 213 | 214 | 216 (184–235) | |
| Hs-CRP (mg l−1) | 2.5 (0.9–6.4) | 2.55 | 2.40 | 0.72 (0.27–1.14) | |
| P-glucose (mM) | 6.4 (5.6–7.7) | 6.3 | 6.5 | 5.4 (5.0–5.6) | |
| Creatinine (μM) | 80 (70–93) | 79 | 86* | 70 (63–84) | |
| eGFR (ml min−1 1.73m−2) | 79 ± 20 | 80 ± 19 | 76 ± 22 | 89 ± 14 | |
| LDL-cholesterol (mM) | 3.2 ± 0.9 | 3.3 ± 1.0 | 3.0 ± 0.8* | 3.6 ± 0.8 | |
IS, ischemic stroke; TIA, transient ischemic attack; IHD, ischemic heart disease; NIHSS, National Institute of Health Stroke Scale; BMI, body mass index; eGFR, estimated glomerular filtration rate
* signifies statistical probability p < 0.0001